The utility of drug checking services as monitoring tools and more: A response to Pirona et al. is a response to the article titled New psychoactive substances: Current health-related practices and challenges in responding to use and harms in Europe by Pirona et al. It argues that although it’s important to recognise the limitations of self-evaluation of drug checking services conducted in a constrained funding environment, we believe that a more balanced view of these services could better inform readers of the International Journal of Drug Policy.
ResearchTags
2C-B
2C-X
alcohol
alprazolam
amphetamine
anxiety
benzodiacepine
bipolar
buprenorphine
bupropion
cannabis
cocaine
depression
DMT
drug checking service
drug testing
ecstasy
fentanyl
GBL
GHB
heroin
isotretinoin
ketamine
lidocaine
LSD
MDMA
memory
mephedrone
methadone
methamphetamine
methylone
methylphenidate
morphine
mushroom
NBOME
NPS
opiates
opium
oxandrolone
oxycodone
schizophrenia
speed
steroids
testosterone
tramadol
Recent posts
- Recent Adware Attack on site 16 December, 2020
- Back in Business & Overhaul 4 June, 2020
- Drug Crypto Markets at CND63 27 March, 2020
- Update regarding COVID-19 23 March, 2020
- Delays with our HPLC analyses 13 February, 2020
- Changes to how/when we quantify some substances 12 January, 2020